The impact of cyclosporine on the development of immunosuppressive therapy for pediatric liver transplantation.
Since the introduction of cyclosporine into pediatric liver transplantation remarkable progress in patient and graft survival has been observed: survival rates 60%; acute (60%), steroid-resistant (22%) and chronic rejection (4%); infections (60%); and side effects (20%). Individualization of cyclosporine therapy complements the development of new immunosuppressive agents such as tacrolimus, mycophenolate mofetil, and sirolimus for specific indications. The ultimate goal of transplantation to achieve immunotolerance a waits future progress.
Burdelski
M M
MM
Universitätsklinikum Hamburg-Eppendorf, Department of Pediatrics, Hamburg, Germany. burdelsk@uke.uni-hamburg.de
D000208:Acute Disease; D002648:Child; D002908:Chronic Disease; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000276:immunology* / Q000401:mortality; D012189:Retrospective Studies; D016019:Survival Analysis
D007166:Immunosuppressive Agents; D016572:Cyclosporine